Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K.

Lancet HIV. 2019 Jul 12. pii: S2352-3018(19)30149-3. doi: 10.1016/S2352-3018(19)30149-3. [Epub ahead of print]

PMID:
31307948
2.

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.

Mehta R, Wolstenholme A, Di Lullo K, Fu C, Joshi S, Crauwels H, Givens N, Vanveggel S, Wynne B, Adkison K.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00748-18. doi: 10.1128/AAC.00748-18. Print 2018 Sep.

3.

Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.

Adkison K, Wolstenholme A, Lou Y, Zhang Z, Eld A, Perger T, Vangerow H, Hayward K, Shaefer M, McCoig C.

Clin Pharmacol Ther. 2018 Mar;103(3):402-408. doi: 10.1002/cpt.943. Epub 2017 Dec 11.

4.

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.

Adkison KK, Gan J, Elko-Simms L, Gardner S, Dumont E, Jones LS, Saunders J, Marbury T, Smith W, Berg J, Galloway C, Stump PJ.

J Clin Pharmacol. 2015 Sep;55(9):1042-50. doi: 10.1002/jcph.512. Epub 2015 May 25.

PMID:
25857714
5.

A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.

Wilfret DA, Walker J, Voitenleitner C, Baptiste-Brown S, Lovern M, Kim J, Adkison K, Shotwell B, Mathis A, Moss L, Lee D, Yu L, Gan J, Spaltenstein A.

Clin Pharmacol Drug Dev. 2014 Nov;3(6):439-48. doi: 10.1002/cpdd.142. Epub 2014 Oct 20.

PMID:
27129119
6.

Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.

Adkison KK, Jones LS, Lou Y, Gan J, Wilfret DA.

Clin Pharmacol Drug Dev. 2014 Sep;3(5):338-45. doi: 10.1002/cpdd.104. Epub 2014 Feb 18.

PMID:
27129005
7.

Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua O.

Br J Clin Pharmacol. 2014 May;77(5):861-72. doi: 10.1111/bcp.12247.

8.

A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.

Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua O.

Br J Clin Pharmacol. 2014 May;77(5):852-60. doi: 10.1111/bcp.12246.

9.
10.

Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1.

Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M, Culp A, Goljer I, Spreen W.

Antimicrob Agents Chemother. 2013 Oct;57(10):5037-44. doi: 10.1128/AAC.00910-13. Epub 2013 Jul 29.

11.

Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.

Wilfret DA, Adkison KK, Jones LA, Lou Y, Gan J, Spreen W.

Antimicrob Agents Chemother. 2013 Oct;57(10):5141-3. doi: 10.1128/AAC.00668-13. Epub 2013 Jul 15.

12.

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.

Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS; ARROW Trial Team.

Clin Pharmacol Ther. 2012 Feb;91(2):272-80. doi: 10.1038/clpt.2011.225. Epub 2011 Dec 21.

PMID:
22190066
13.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4090-110. doi: 10.1002/jps.22552. Epub 2011 May 3.

PMID:
21541938
14.

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Yates JW.

J Pharm Sci. 2011 Oct;100(10):4127-57. doi: 10.1002/jps.22550. Epub 2011 May 3.

PMID:
21541937
15.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.

Poulin P, Jones HM, Jones RD, Yates JW, Gibson CR, Chien JY, Ring BJ, Adkison KK, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Ku MS.

J Pharm Sci. 2011 Oct;100(10):4050-73. doi: 10.1002/jps.22554. Epub 2011 Apr 26.

PMID:
21523782
16.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.

Vuppugalla R, Marathe P, He H, Jones RD, Yates JW, Jones HM, Gibson CR, Chien JY, Ring BJ, Adkison KK, Ku MS, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4111-26. doi: 10.1002/jps.22551. Epub 2011 Apr 7.

PMID:
21480234
17.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.

Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4074-89. doi: 10.1002/jps.22553. Epub 2011 Mar 30.

PMID:
21452299
18.

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.

Musiime V, Kendall L, Bakeera-Kitaka S, Snowden WB, Odongo F, Thomason M, Musoke P, Adkison K, Burger D, Mugyenyi P, Kekitiinwa A, Gibb DM, Walker AS; ARROW Trial team.

Antivir Ther. 2010;15(8):1115-24. doi: 10.3851/IMP1695.

PMID:
21149918
19.

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.

Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, Lou Y, Lee EJ.

J Pharm Sci. 2010 Feb;99(2):1046-62. doi: 10.1002/jps.21860.

PMID:
19569219
20.

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).

Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team.

HIV Med. 2009 Feb;10(2):116-24. doi: 10.1111/j.1468-1293.2008.00660.x.

21.

In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.

Demarest JF, Sparks SS, Schell K, Shibayama S, McDanal CB, Fang L, Adkison KK, Shachoy-Clark A, Piscitelli SC.

J Clin Pharmacol. 2008 Oct;48(10):1179-88. doi: 10.1177/0091270008322178. Epub 2008 Aug 1.

PMID:
18676693
22.

The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.

Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Lou Y, Lee EJ.

Br J Clin Pharmacol. 2008 Aug;66(2):233-9. doi: 10.1111/j.1365-2125.2008.03184.x. Epub 2008 Apr 22.

23.

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).

Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, Kabeya K, Clumeck N.

Antimicrob Agents Chemother. 2008 Mar;52(3):858-65. Epub 2007 Dec 10.

24.

Monitoring liver safety in drug development: the GSK experience.

Hunt CM, Papay JI, Edwards RI, Theodore D, Alpers DH, Dollery C, Debruin TW, Adkison KK, Stirnadel HA, Gibbs TG.

Regul Toxicol Pharmacol. 2007 Nov;49(2):90-100. Epub 2007 Jun 21.

PMID:
17655994
25.

Synthesis and evaluation of potent and selective beta3 adrenergic receptor agonists containing heterobiaryl carboxylic acids.

Shearer BG, Chao EY, Uehling DE, Deaton DN, Cowan C, Sherman BW, Milliken T, Faison W, Brown K, Adkison KK, Lee F.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4670-7. Epub 2007 May 25.

PMID:
17560786
26.

The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.

Adkison KK, Shachoy-Clark A, Fang L, Lou Y, Otto VR, Berrey MM, Piscitelli SC.

Br J Clin Pharmacol. 2006 Sep;62(3):336-44.

27.

Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.

Uehling DE, Shearer BG, Donaldson KH, Chao EY, Deaton DN, Adkison KK, Brown KK, Cariello NF, Faison WL, Lancaster ME, Lin J, Hart R, Milliken TO, Paulik MA, Sherman BW, Sugg EE, Cowan C.

J Med Chem. 2006 May 4;49(9):2758-71.

PMID:
16640337
28.

Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.

Johnson BM, Song IH, Adkison KK, Borland J, Fang L, Lou Y, Berrey MM, Nafziger AN, Piscitelli SC, Bertino JS Jr.

J Clin Pharmacol. 2006 May;46(5):577-87.

PMID:
16638741
29.

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

Adkison KK, Barrett DG, Deaton DN, Gampe RT, Hassell AM, Long ST, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Wells-Knecht KJ, Willard DH Jr, Wright LL.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. Epub 2005 Nov 15.

PMID:
16290936
30.

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.

Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S.

AIDS. 2005 Sep 23;19(14):1443-8.

PMID:
16135896
31.

Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.

Adkison KK, Shachoy-Clark A, Fang L, Lou Y, O'Mara K, Berrey MM, Piscitelli SC.

Antimicrob Agents Chemother. 2005 Jul;49(7):2802-6.

32.

Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.

Shen DD, Artru AA, Adkison KK.

Adv Drug Deliv Rev. 2004 Oct 14;56(12):1825-57. Review.

PMID:
15381336
33.

Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.

Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, Polli JW.

Pharmacology. 2004 Oct;72(2):92-8.

PMID:
15331914
34.

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.

J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.

PMID:
12438524
35.

Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.

Uehling DE, Donaldson KH, Deaton DN, Hyman CE, Sugg EE, Barrett DG, Hughes RG, Reitter B, Adkison KK, Lancaster ME, Lee F, Hart R, Paulik MA, Sherman BW, True T, Cowan C.

J Med Chem. 2002 Jan 31;45(3):567-83.

PMID:
11806709
36.

High-throughput screening for lead optimization: a rational approach.

Bajpai M, Adkison KK.

Curr Opin Drug Discov Devel. 2000 Jan;3(1):63-71.

PMID:
19649839
37.

Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.

Henke BR, Adkison KK, Blanchard SG, Leesnitzer LM, Mook RA Jr, Plunket KD, Ray JA, Roberson C, Unwalla R, Willson TM.

Bioorg Med Chem Lett. 1999 Dec 6;9(23):3329-34.

PMID:
10612594
38.

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.

Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM.

Diabetes. 1999 Jul;48(7):1415-24.

PMID:
10389847
39.

Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships.

Shaffer JE, Adkison KK, Halm K, Hedeen K, Berman J.

J Pharm Sci. 1999 Mar;88(3):313-8.

PMID:
10052989
40.

Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parameters.

Adkison KK, Halm KA, Shaffer JE, Drewry D, Sinhababu AK, Berman J.

Pharm Biotechnol. 1998;11:423-43. Review. No abstract available.

PMID:
9760690
41.

Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbits.

Scism JL, Powers KM, Artru AA, Chambers AC, Lewis L, Adkison KK, Kalhorn TF, Shen DD.

Drug Metab Dispos. 1997 Dec;25(12):1337-46.

PMID:
9394022
42.

Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput.

Berman J, Halm K, Adkison K, Shaffer J.

J Med Chem. 1997 Mar 14;40(6):827-9. No abstract available.

PMID:
9083469
43.

Effect of para-aminohippurate on the efflux of valproic acid from the central nervous system of the rabbit.

Adkison KD, Powers KM, Artru AA, Shen DD.

Epilepsy Res. 1996 Mar;23(2):95-104.

PMID:
8964279
44.

Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter.

Adkison KD, Shen DD.

J Pharmacol Exp Ther. 1996 Mar;276(3):1189-200.

PMID:
8786552
45.

Distribution of unsaturated metabolites of valproate in human and rat brain--pharmacologic relevance?

Adkison KD, Ojemann GA, Rapport RL, Dills RL, Shen DD.

Epilepsia. 1995 Aug;36(8):772-82.

PMID:
7635096
46.

Role of choroid plexus epithelium in the removal of valproic acid from the central nervous system.

Adkison KD, Artru AA, Powers KM, Nochlin D, Shen DD.

Epilepsy Res. 1995 Mar;20(3):185-92.

PMID:
7796790

Supplemental Content

Loading ...
Support Center